Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enzalutamide + toripalimab + testosterone
- Development stage
- Unknown
- Lead developer
- Beijing Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
enzalutamide + toripalimab + testosterone is an experimental combination therapy regimen being investigated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This regimen incorporates Bipolar Androgen Therapy (BAT), which involves the administration of high-dose testosterone to rapidly cycle serum levels between supraphysiologic and castrate concentrations. This cycling is intended to disrupt androgen receptor (AR) signaling and induce DNA damage in prostate cancer cells. The regimen further includes enzalutamide, a second-generation AR antagonist that inhibits androgen binding, nuclear translocation, and DNA binding, and toripalimab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. The combination aims to leverage the potential of BAT to sensitize tumors to AR inhibition and enhance the anti-tumor immune response facilitated by checkpoint blockade. This specific triplet is primarily being developed and studied by researchers at Beijing Hospital.
- Brand names
- Tuoyi
- Other names
- Bipolar Androgen Therapy + Toripalimab + Enzalutamide
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on enzalutamide + toripalimab + testosterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enzalutamide + toripalimab + testosterone.